At Prism, we recognize cardiovascular disease represents the most prevalent series of conditions causing morbidity and mortality in the US population. More US residents suffer from and die from cardiovascular disease than from any other disorder, including all forms of cancer combined.

Specifically, Prism believes there is an opportunity for a company to successfully adopt a specialty approach to the cardiovascular acute care marketplace, with product solutions that fulfill the medical needs of patients and healthcare providers.

1150 First Avenue, Suite 1050 • King of Prussia, PA 19406
Phone: (610) 265-7710 • Fax: (610)265-7706
Email: info@prismpharma.com


Latest News

 


Prism Pharmaceuticals Raises $68 Million to Advance Acute Care Portfolio


Prism Pharmaceuticals, Inc. has secured up to $68 million in capital from Paul Capital Partners' Paul Royalty Fund II, L.P. and existing investor Essex Woodlands Health Ventures Fund VI.

learn more>

 

©Copyright 2006 Prism Pharmaceuticals, Inc. All rights reserved.